AimedBio Accelerates ADC Development with Proprietary Platform

AimedBio is expected to accelerate antibody-drug conjugate (ADC) development after validating its platform and capabilities through pipeline licensing deals with global pharmaceutical companies.

In a report released on the 12th, Jung Yu-kyung, an analyst at Shinyoung Securities, stated that "AimedBio possesses the proprietary P-ADC platform based on patient-derived cells (PDC) and patient-derived xenograft (PDX) models, giving it the capability to accelerate ADC development." The PDC/PDX system is optimized for ADC design based on actual patient-derived models and enables sophisticated clinical trial design through data analysis, shortening development time and increasing success probability.

AimedBio, spun off from Samsung Seoul Hospital in 2018, develops ADC anticancer drugs and has been building competitiveness by developing its pipeline through its proprietary PDC/PDX platform.

According to Shinyoung Securities, AimedBio is currently conducting Phase 1 clinical trials for FGFR3 ADC (AMB302), which was licensed to Biohaven. An asset licensed to Boehringer Ingelheim (target undisclosed) is expected to enter Phase 1 trials this year. ROR1 ADC (AMB303), licensed to SK Plasma, is expected to file an Investigational New Drug (IND) application within the year. "The advantage of models built with big data from actual patient samples is expected to yield high success rates in clinical stage transitions," Jung said. "There is also high potential for synergies with Samsung Biologics' needs to accelerate ADC development."

Through technology licensing to global companies, AimedBio has received upfront payments and milestone payments, building cash reserves of 180 billion won ($130 million) as of the end of 2025. This enables an aggressive R&D strategy, and the possibility of preclinical-stage licensing for three additional drug candidates could be determined as early as this year, according to Jung's analysis.

However, Jung added that the overhang from approximately 10 million shares released from lockup on the 4th of last month remains a risk factor. While supply-demand instability is limited due to inclusion in the KOSDAQ 150 index and resulting KOSDAQ Active ETF portfolios, the high overhang could weigh on further stock price gains.